Illinois Ventures

Type

Venture Capital

Status

Active

Location

Chicago, United States

Total investments

58

Average round size

6M

Portfolio companies

44

Rounds per year

2.42

Lead investments

4

Follow on index

0.24

Exits

9

Stages of investment
SeedEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareAnalyticsHealth CareHealth DiagnosticsSaaSHardwareAdvertisingEnergyRenewable Energy

Summary

Illinois Ventures is the famous VC, which was founded in 2002. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Chicago.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Illinois Ventures, startups are often financed by Serra Ventures, SOSV, RPM Ventures. The meaningful sponsors for the fund in investment in the same round are Serra Ventures, RPM Ventures, Intersouth Partners. In the next rounds fund is usually obtained by SOSV, HAX, West Capital Advisors.

The overall number of key employees were 1.

Among the most successful fund investment fields, there are Biotechnology, Therapeutics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline ShareThis, Chromatin, Diagnostic Photonics

The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 13 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2011. Despite it in 2019 the fund had an activity. This Illinois Ventures works on 9 percentage points less the average amount of lead investments comparing to the other organizations. The higher amount of exits for fund were in 2011. The usual things for fund are deals in the range of 5 - 10 millions dollars.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesAI/Big DataCloud/InfrastructureHealthcare
Stage focus
SeedSeries ASeries B
Geo focus
United States

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
58
Lead investments
4
Exits
9
Rounds per year
2.42
Follow on index
0.24
Investments by industry
  • Biotechnology (12)
  • Software (10)
  • Health Care (9)
  • Renewable Energy (8)
  • Advertising (6)
  • Show 88 more
Investments by region
  • United States (55)
Peak activity year
2011

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
12
Avg. valuation at time of investment
431K
Group Appearance index
0.86
Avg. company exit year
7

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Caden Biosciences 07 Sep 2006 Biotechnology Early Stage Venture 5M
Predicine Huidu Medical Technology 06 Aug 2018 Health Care, Medical Early Stage Venture 0 China, Fengxian District
Elion Therapeutics 17 Jun 2024 Early Stage Venture 81M United States, Massachusetts, Boston

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.